Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia - PubMed (original) (raw)

Clinical Trial

. 2004 Aug 15;170(4):440-4.

doi: 10.1164/rccm.200311-1578OC. Epub 2004 Jun 7.

Victor L Yu, Keith P Klugman, Charles Feldman, Ake Ortqvist, Jordi Rello, Arthur J Morris, Carlos M Luna, David R Snydman, Wen Chien Ko, M Bernadete F Chedid, David S Hui, Antoine Andremont, Christine C C Chiou; International Pneumococcal Study Group

Affiliations

• PMID: 15184200
• DOI: 10.1164/rccm.200311-1578OC

Clinical Trial

Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia

Larry M Baddour et al. Am J Respir Crit Care Med. 2004.

Abstract

Retrospective studies have suggested that combination antibiotic therapy for severe bacteremic pneumococcal pneumonia may reduce mortality. We assessed this issue in a prospective, multicenter, international observational study of 844 adult patients with bacteremia due to Streptococcus pneumoniae. The effect of combination antibiotic therapy versus monotherapy on mortality was examined by univariate analyses and by logistic regression models. The 14-day mortality was not significantly different for the two groups. However, among critically ill patients, combination antibiotic therapy was associated with lower 14-day mortality (23.4 versus 55.3%, p = 0.0015). This improvement in survival was independent of country of origin, intensive care unit support, class of antibiotics, or in vitro activity of the antibiotics prescribed. Combination antibiotic therapy improved survival among critically ill patients with bacteremic pneumococcal illness.

PubMed Disclaimer

Comment in

• Antibiotic therapy and outcome in critically ill patients with pneumococcal bacteremia.
  Depuydt P, Benoit D, Vandewoude K, Decruyenaere J. Depuydt P, et al. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1472; author reply 1474. doi: 10.1164/ajrccm.172.11.1472. Am J Respir Crit Care Med. 2005. PMID: 16301302 No abstract available.
• Potential mechanisms for mortality reduction associated with combination antibiotic therapy among severely ill patients with pneumococcal bacteremia.
  Schwartz DN. Schwartz DN. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1472-3; author reply 1474. doi: 10.1164/ajrccm.172.11.1472a. Am J Respir Crit Care Med. 2005. PMID: 16301303 No abstract available.
• Is combination the only issue?
  Boussekey N, Faure K, Guery B. Boussekey N, et al. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1473-4; author reply 1474. doi: 10.1164/ajrccm.172.11.1473. Am J Respir Crit Care Med. 2005. PMID: 16301304 No abstract available.

Similar articles

• Potential mechanisms for mortality reduction associated with combination antibiotic therapy among severely ill patients with pneumococcal bacteremia.
  Schwartz DN. Schwartz DN. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1472-3; author reply 1474. doi: 10.1164/ajrccm.172.11.1472a. Am J Respir Crit Care Med. 2005. PMID: 16301303 No abstract available.
• Antibiotic therapy and outcome in critically ill patients with pneumococcal bacteremia.
  Depuydt P, Benoit D, Vandewoude K, Decruyenaere J. Depuydt P, et al. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1472; author reply 1474. doi: 10.1164/ajrccm.172.11.1472. Am J Respir Crit Care Med. 2005. PMID: 16301302 No abstract available.
• Therapy for pneumococcal bacteremia: monotherapy or combination therapy?
  Feldman C, Anderson R. Feldman C, et al. Curr Opin Infect Dis. 2009 Apr;22(2):137-42. doi: 10.1097/QCO.0b013e3283232a30. Curr Opin Infect Dis. 2009. PMID: 19276880 Review.
• An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.
  Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP; International Pneumococcal Study Group. Yu VL, et al. Clin Infect Dis. 2003 Jul 15;37(2):230-7. doi: 10.1086/377534. Epub 2003 Jul 7. Clin Infect Dis. 2003. PMID: 12856216

Cited by

• Systematic analysis of drug combinations against Gram-positive bacteria.
  Cacace E, Kim V, Varik V, Knopp M, Tietgen M, Brauer-Nikonow A, Inecik K, Mateus A, Milanese A, Mårli MT, Mitosch K, Selkrig J, Brochado AR, Kuipers OP, Kjos M, Zeller G, Savitski MM, Göttig S, Huber W, Typas A. Cacace E, et al. Nat Microbiol. 2023 Nov;8(11):2196-2212. doi: 10.1038/s41564-023-01486-9. Epub 2023 Sep 28. Nat Microbiol. 2023. PMID: 37770760 Free PMC article.
• Severe community-acquired pneumonia.
  Niederman MS, Torres A. Niederman MS, et al. Eur Respir Rev. 2022 Dec 14;31(166):220123. doi: 10.1183/16000617.0123-2022. Print 2022 Dec 31. Eur Respir Rev. 2022. PMID: 36517046 Free PMC article. Review.
• The Pattern of Antimicrobial Prescription at a Tertiary Health Center in Egypt: A Point Survey and Implications.
  Ashour RH, Abdelkader EA, Hamdy O, Elmetwally M, Laimon W, Abd-Elaziz MA. Ashour RH, et al. Infect Drug Resist. 2022 Oct 31;15:6365-6378. doi: 10.2147/IDR.S380693. eCollection 2022. Infect Drug Resist. 2022. PMID: 36337931 Free PMC article.
• The Effect of Macrolides on Mortality in Bacteremic Pneumococcal Pneumonia: A Retrospective, Nationwide Cohort Study, Israel, 2009-2017.
  Chowers M, Gerassy-Vainberg S, Cohen-Poradosu R, Wiener-Well Y, Bishara J, Maor Y, Zimhony O, Chazan B, Gottesman BS, Dagan R, Regev-Yochay G; IAIPD research group. Chowers M, et al. Clin Infect Dis. 2022 Dec 19;75(12):2219-2224. doi: 10.1093/cid/ciac317. Clin Infect Dis. 2022. PMID: 35443039 Free PMC article.
• Comparison of prognostic factors between bacteraemic and non-bacteraemic critically ill immunocompetent patients in community-acquired severe pneumococcal pneumonia: a STREPTOGENE sub-study.
  Bellut H, Porcher R, Varon E, Asfar P, Le Tulzo Y, Megarbane B, Mathonnet A, Dugard A, Veinstein A, Ouchenir K, Siami S, Reignier J, Galbois A, Cousson J, Preau S, Baldesi O, Rigaud JP, Souweine B, Misset B, Jacobs F, Dewavrin F, Mira JP, Bedos JP. Bellut H, et al. Ann Intensive Care. 2021 Oct 24;11(1):148. doi: 10.1186/s13613-021-00936-z. Ann Intensive Care. 2021. PMID: 34689255 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information